Please assess the completion status of the following clinical trial:

Trial Title: Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (177001/P06472/MK-8265-013)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal women, defined as:~  * 12 months of spontaneous amenorrhea;~ * OR 6 months of spontaneous amenorrhea with serum Follicle Stimulating Hormone (FSH) levels \>40 mIU/mL;~ * OR 6 weeks post surgical bilateral oophorectomy with or without hysterectomy.~* Be ≥ 40 and ≤ 65 years of age;~* Have a body mass index (BMI) ≥ 18 and ≤ 32 kg/m\^2;~* Minimum of 7 moderate to severe hot flushes per day or 50 per week, as quantified from daily diary recordings during at least 7 days preceding randomization to trial medication;~* Able to handle the electronic diary device after training and having at least 80% compliance on complete daily diary entries during the period prior to randomization;~* Give voluntary written Informed Consent (IC) after the scope and nature of the investigation had been explained, before screening evaluations.~Exclusion Criteria:~* History or presence of any malignancy, except non-melanoma skin cancers;~* Any clinically unstable or uncontrolled renal, hepatic, endocrine, respiratory, hematological, neurological, cardiovascular or cerebrovascular disease that would put the subject at safety risk or mask measure of efficacy;~* History of seizures or epilepsy;~* History or presence of clinically significant depression or other psychiatric disorder which, in the opinion of the investigator, might compromise or confound the subject's participation in the trial;~* Abnormal clinically relevant vaginal bleeding;~* Any clinically relevant (opinion of investigator) abnormal finding during physical, gynecological and breast examination at screening;~* Abnormal, clinically significant results of mammography;~* Abnormal cervical smear test results (corresponding to Pap III and higher, including Low-Grade Squamous Intraepithelial Lesion (LSIL), High-Grade Squamous Intraepithelial Lesion (HSIL), Cervical Intraepithelial Neoplasia (CIN) 1 and higher);~* Hematological or biochemical values at screening outside the reference ranges considered clinically relevant in the opinion of the investigator;~* High Blood Pressure (BP);~* Use of any drug product containing estrogens, progestins, androgens or tibolone prior to screening (and up to and including randomization) within a pre-specified period;~* Any of the following treatments within the last 4 weeks prior to screening (and up to and including randomization):~  * tricyclic antidepressants, Serotonin Noradrenergic Reuptake Inhibitors (SNRIs), SSRIs, Monoamine Oxidase (MAO)-inhibitors, mirtazapine~ * antianxiety drugs, antipsychotics~ * coumarin-derivatives~ * α-adrenergic agents~ * β-blockers~ * dopamine agonists/antagonists~ * opiates, barbiturates~ * raloxifene~ * homeopathic menopausal preparations or other preparations intended to treat climacteric or Central Nervous System (CNS) symptoms~ * hepatic microsomal enzyme-inducing drugs or drugs known to affect or interfere with the pharmacokinetics of mirtazapine;~* Any condition or disease that could affect or interfere with the pharmacokinetics of mirtazapine;~* Subjects sensitive to trial medication or its components;~* Use of any investigational drug and/or participation in another clinical trial within the last eight weeks prior to screening;~* History of alcohol and/or drug abuse within the last two years prior to screening.

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants receive encapsulated tablets, orally, once daily (QD) for up to 12 weeks.
- Esmirtazapine 2.25 mg (Type: EXPERIMENTAL): Participants receive esmirtazapine, 2.25 mg, encapsulated tablets, orally QD for up to 12 weeks.
- Esmirtazapine 4.5 mg (Type: EXPERIMENTAL): Participants receive esmirtazapine, 4.5 mg, encapsulated tablets, orally QD for up to 12 weeks.
- Esmirtazapine 9 mg (Type: EXPERIMENTAL): Participants receive esmirtazapine, 9 mg, encapsulated tablets, orally QD for up to 12 weeks.
- Esmirtazapine 18 mg (Type: EXPERIMENTAL): Participants receive esmirtazapine, 18 mg, encapsulated tablets, orally QD for up to 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).